Related Experiment Video

Updated: Nov 9, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K

Neonates With SARS-CoV-2 Infection and Pulmonary Disease Safely Treated With Remdesivir

Bedangshu Saikia1, Julian Tang2, Simon Robinson1

  • 1From the Paediatric Intensive Care, Leicester Children's Hospital, Leicester, United Kingdom.

The Pediatric Infectious Disease Journal
|April 13, 2021
PubMed

Insights

Two premature infants with severe SARS-CoV-2 pulmonary disease, presenting with apnea, were successfully treated with remdesivir (RDV). This highlights RDV

Area of Science:

  • Neonatology
  • Pediatric Infectious Diseases
  • Pulmonology

Background:

  • Premature infants are a high-risk group for severe outcomes from SARS-CoV-2 infection.
  • Respiratory distress and apnea are potential early symptoms in neonates with SARS-CoV-2.

Observation:

  • Two extremely premature infants presented with recurrent apnea and progressed to severe SARS-CoV-2-related pulmonary disease requiring mechanical ventilation.
  • Both infants received compassionate use of remdesivir (RDV) for treatment.

Findings:

  • Successful treatment of severe SARS-CoV-2 pulmonary disease in two neonates using remdesivir (RDV).
  • No adverse side effects were observed during RDV treatment in these high-risk infants.
  • Early recognition of potential deterioration and multidisciplinary team involvement are crucial for timely intervention.

Implications:

  • SARS-CoV-2 infection can manifest as apnea and progress to severe pulmonary disease in neonates.
  • Remdesivir (RDV) appears to be a safe and effective treatment option for severe SARS-CoV-2 in this population.
  • Experience informs the development of guidelines for RDV use in children under 12, especially infants.

More Related Videos

A Swine Model of Neonatal Asphyxia10:36

A Swine Model of Neonatal Asphyxia

Published on: October 11, 2011

14.6K
Intratracheal Instillation of Stem Cells in Term Neonatal Rats04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

5.8K

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
615
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
554
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
453
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
522
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
270
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
324